Ch Biotech R And D Co
Ch Biotech R&D Co., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia. Founded in 2002, the company has established itself as a pioneer in biopharmaceutical research and development, focusing on innovative solutions for healthcare challenges. Specialising in the development of biologics and biosimilars, Ch Biotech R&D Co. is recognised for its commitment to quality and scientific excellence. Their core products include advanced therapeutic proteins and monoclonal antibodies, which are distinguished by their efficacy and safety profiles. With a strong market position, Ch Biotech R&D Co. has achieved significant milestones, including successful collaborations with global pharmaceutical firms. Their dedication to research and development continues to drive advancements in the biotechnology industry, making them a trusted name in biopharmaceutical innovation.
DitchCarbon Score
How does Ch Biotech R And D Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ch Biotech R And D Co's score of 21 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ch Biotech R And D Co's reported carbon emissions
In 2022, Ch Biotech R And D Co, headquartered in Taiwan (TW), reported total carbon emissions of approximately 3,260,880 kg CO2e. This figure includes 437,910 kg CO2e from Scope 1 emissions, 3,260,880 kg CO2e from Scope 2 emissions, and 140,920 kg CO2e from Scope 3 emissions. Comparatively, in 2021, the company recorded total emissions of about 4,444,390 kg CO2e, with Scope 1 emissions at 444,390 kg CO2e, Scope 2 emissions at 3,458,040 kg CO2e, and Scope 3 emissions at 92,920 kg CO2e. This indicates a reduction in total emissions from 2021 to 2022, showcasing a commitment to lowering their carbon footprint. Despite these reductions, Ch Biotech R And D Co has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on improving its emissions reporting and management practices as part of its broader climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 444,390 | 000,000 |
| Scope 2 | 3,458,040 | 0,000,000 |
| Scope 3 | 92,920 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ch Biotech R And D Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
